archived version — not current
This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-23. It does not reflect the current, live profile. View the current profile.
Teduglutide
Snapshot captured 2026-09-23 — Published content materially edited
Overview
Teduglutide is a GLP-2 analog studied in short bowel syndrome and intestinal failure. The clinical question concerns outcomes such as parenteral support and patient experience in defined populations.
Evidence quality
WPF’s atlas includes pediatric case reports, observational cohorts of adults, and monitoring guidance for people receiving teduglutide. These sources can inform questions about long-term care, but a case report or observational association cannot alone establish the size of a causal treatment effect.
Safety concerns
This Directory entry has no published source-linked citations or jurisdiction-specific regulatory records. Adults and children, differing underlying anatomy, parenteral-support outcomes, and safety monitoring must be assessed separately against primary and official sources.
Citations as of this version
- Development of Teduglutide purity certified reference material (GBW09342) through amino acid-based isotope dilution mass spectrometry and sulfur-based isotope dilution inductively coupled plasma mass spectrometry. (2027)
- Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance. (2026)
- Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study. (2026)
- [Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group "Chronic intestinal failure" of the Society for Paediatric Gastroenterology and Nutrition (GPGE)]. (2026)
- Teduglutide use in haemodialysis-dependent renal failure from secondary hyperoxaluria in short bowel syndrome and type 3 intestinal failure - A case report. (2026)
- Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review. (2026)
- Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment. (2026)
- Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience. (2026)
- Association between teduglutide treatment and long-term reductions in parenteral support: An observational cohort study of adults with short bowel syndrome. (2026)
- Development of a consensus parenteral solution weaning algorithm for children with short-bowel syndrome associated intestinal failure responding to teduglutide therapy. (2026)
- Optimizing teduglutide treatment regimens in children with short bowel syndrome. (2026)
- Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment. (2026)
- Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide. (2026)
- Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients. (2026)
- A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome. (2026)
- Efficacy and safety of teduglutide in children with short bowel syndrome: a narrative review. (2026)
- Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure. (2026)
- Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide. (2025)
- Impact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis. (2025)
- Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study. (2025)
- Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis. (2025)
- Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome. (2025)
- Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine. (2025)
- Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey. (2025)
- Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries. (2025)
- Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic. (2025)
- Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study. (2025)
- Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. (2025)
- Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions. (2025)
- Long-term outcomes and adverse effects of teduglutide in patients with short bowel syndrome: Highlighting hyperamylasemia and hyperlipasemia. (2024)
- Reversal of Intestinal Failure With Teduglutide in <i>PERCC1</i>-Associated Enteropathy: A Case Report. (2024)
- Use of teduglutide in adults with short bowel syndrome-associated intestinal failure. (2024)
- Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. (2024)
- Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults. (2024)
- Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease. (2024)
- Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report. (2024)
- Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure. (2024)
- Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study. (2024)
- The Impact of Teduglutide on Real-Life Health Care Costs in Children with Short Bowel Syndrome. (2024)
- Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective. (2024)
- Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden. (2024)
- Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis. (2024)
- Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals. (2024)
- Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension. (2023)
- [Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome]. (2023)
- Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support. (2023)
- Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome. (2023)
- Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications. (2023)
- Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort study. (2023)
- Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome. (2023)
- Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure. (2023)
- Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study. (2023)
- Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing. (2023)
- The indications and results of the use of teduglutide in patients with short bowel. (2023)
- Nutritional management of a patient with chronic intestinal failure and hemodialysis receiving teduglutide: A case report. (2023)
- Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome. (2023)
- Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy. (2023)
- [Review of real-life teduglutide experience]. (2023)
- Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring. (2023)
- Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes. (2023)
- Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure. (2023)
- Teduglutide for the treatment of short bowel syndrome: a double-edged sword? (2023)
- Teduglutide in short bowel syndrome patients: A way back to normal life? (2022)
- Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up. (2022)
- Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program. (2022)
- Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide. (2022)
- Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP). (2022)
- Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis. (2022)
- Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers. (2022)
- Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study. (2022)
- The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience. (2022)
- Characterization of American teduglutide consumers from 2015 to 2020: A large database study. (2022)
- Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS. (2022)
- Use of Teduglutide in Children With Intestinal Failure: A Systematic Review. (2022)
- De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report. (2021)
- Expression, purification and molecular dynamics simulation of extracellular domain of glucagon-like peptide-2 receptor linked to teduglutide. (2021)
- Designing Novel Teduglutide Analogues with Improved Binding Affinity: An In Silico Peptide Engineering Approach. (2021)
- Teduglutide for pediatric short bowel syndrome patients. (2021)
- Intestinal iatrogenic hyperadaptation in patients with short bowel syndrome and Crohn's disease: Is this an indication for mandatory lifelong injections of teduglutide? (2021)
- Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure. (2021)
- Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn's Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared. (2021)
- Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support. (2021)
- Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies. (2021)
- Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. (2021)
- Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis. (2021)
- Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome. (2021)
- Long-Term Outcomes With Teduglutide From a Single Center. (2021)
- Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials. (2020)
- GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives. (2020)
- Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials. (2020)
- Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. (2020)
- Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data. (2020)
- [Is there life after teduglutide?] (2020)
- Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study. (2020)
- Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. (2020)
- Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study. (2020)
- Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency. (2020)
- The Glucagon-Like Peptide 2 Analog Teduglutide Reversibly Associates to Form Pentamers. (2020)
- Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature. (2020)
- Small-Bowel Adaptation: A Case of Morphological Changes Induced by Teduglutide in Short-Bowel Syndrome With Intestinal Failure. (2020)
- Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series. (2020)
- Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report. (2020)
- Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study. (2020)
- Experience with teduglutide treatment for short bowel syndrome in clinical practice. (2019)
- Effect of teduglutide on restoring oral autonomy for magnesium in two patients with short bowel. (2019)
- Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature. (2019)
- Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome. (2019)
- Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption. (2019)
- Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study. (2018)
- De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report. (2018)
- Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. (2018)
- Tissular growth factors profile after teduglutide administration on an animal model of intestinal anastomosis. (2018)
- Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome. (2018)
- Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series. (2018)
- Teduglutide for the treatment of short bowel syndrome - a safety evaluation. (2018)
- GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting. (2018)
- Teduglutide-induced stem cell function in intestinal repair. (2018)
- Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome. (2018)
- Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration. (2018)
- Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access. (2017)
- Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. (2017)
- The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome. (2017)
- Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome. (2017)
- Teduglutide for treatment of adult patients with short bowel syndrome. (2017)
- Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats. (2017)
- Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn's disease. (2017)
- Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. (2017)
- Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure. (2017)
- Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome. (2017)
- Teduglutide effects on gene regulation of fibrogenesis on an animal model of intestinal anastomosis. (2017)
- Teduglutide: A Review in Short Bowel Syndrome. (2017)
- Response to "Teduglutide and Intestinal Permeability in Short Bowel Syndrome". (2016)
- Teduglutide and Intestinal Permeability in Short Bowel Syndrome. (2016)
- Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review. (2016)
- Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy. (2016)
- Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition. (2016)
- Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. (2016)
- A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide. (2016)
- [Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA]. (2015)
- Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials. (2015)
- Teduglutide: a guide to its use in short bowel syndrome. (2015)
- Vortioxetine hydrobromide, crofelemer, and teduglutide. (2014)
- Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome. (2014)
- Teduglutide for the Treatment of Short Bowel Syndrome. (2014)
- A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects. (2014)
- Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome. (2014)
- Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells. (2013)
- [Short bowel syndrome. GLP-2 analog teduglutide]. (2013)
- Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. (2013)
- Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. (2013)
- Pharmacokinetics of teduglutide in subjects with renal impairment. (2013)
- The long road to a new short-bowel therapy: teduglutide for clinical use. (2013)
- Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure. (2013)
- Teduglutide for the treatment of short bowel syndrome. (2013)
- Teduglutide: a review of its use in the treatment of patients with short bowel syndrome. (2013)
- Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. (2013)
- Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects. (2013)
- Teduglutide injection (Gattex) for short bowel syndrome. (2013)
- Treatment of adult short bowel syndrome patients with teduglutide. (2012)
- A Thorough QT Study of Teduglutide in Healthy Subjects. (2012)
- Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night. (2012)
- Teduglutide, a glucagon-like peptide 2 analogue: a novel protective agent with anti-apoptotic and anti-oxidant properties in mice with lung injury. (2012)
- Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. (2012)
- Effect of different doses of GLP-2 (Teduglutide) on acute esophageal lesion due to acid-pepsin perfusion in male rats. (2011)
- Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. (2011)
- Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. (2011)
- Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. (2010)
- Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. (2010)
- Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome. (2010)
- Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. (2009)
- Teduglutide in intestinal adaptation and repair: light at the end of the tunnel. (2008)
- Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. (2008)
- Teduglutide (2006)
- Teduglutide for the treatment of short bowel syndrome. (2006)
- Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. (2005)
- Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. (2004)
Regulatory status as of this version
- European Union — EMA: approved — Revestive (teduglutide) is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. (Per the current SmPC Section 4.1; supersedes the older '1 year and above' figure still shown in the EMA overview page's summary info box as of this research.)
- United States — FDA: approved — GATTEX (teduglutide) is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
Content hash: f4bbb2e6b756319741a7dc8d2dee1fb65fc97673a267a4ee75ae2827e88dd454